NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 180)
Posted On: 08/26/2019 3:40:24 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Secures Agreement with Prominent Biotherapeutics Firm
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life-sciences and other industries, recently executed a contract services agreement with a well-known biotherapeutics firm. An article discussing the company reads, “Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://nnw.fm/n6GTk). . . . PBIO’s BaroFold technology platform offers a unique and cost-effective way to address the complex and often-challenging process of manufacturing the recombinant proteins that are required in the development of protein-based drugs. Two of the major challenges associated with manufacturing recombinant proteins are (1) the formation of aggregates and (2) protein misfolding. These are significant issues that can prevent a protein drug candidate from ever making it to market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life-sciences and other industries, recently executed a contract services agreement with a well-known biotherapeutics firm. An article discussing the company reads, “Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://nnw.fm/n6GTk). . . . PBIO’s BaroFold technology platform offers a unique and cost-effective way to address the complex and often-challenging process of manufacturing the recombinant proteins that are required in the development of protein-based drugs. Two of the major challenges associated with manufacturing recombinant proteins are (1) the formation of aggregates and (2) protein misfolding. These are significant issues that can prevent a protein drug candidate from ever making it to market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼